Amneal Pharma Bets Big on Biosimilars in Q1 Call

Amneal Pharma ((AMRX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Amneal Pharma’s latest earnings call struck an optimistic tone, as management balanced strong current performance with a bold, transformative bet on biosimilars. The pending Kashiv acquisition was framed as a pivotal move that broadens scale, deepens capabilities, and extends the company’s growth runway, even as executives acknowledged near‑term dilution, higher CapEx, and integration risks.

Strategic Acquisition Creating a Global Biosimilars Platform

Amneal unveiled a deal to acquire Kashiv BioSciences for $750 million upfront, split evenly between cash and equity, plus up to $350 million in milestones and potential royalties. Management said the combination will create a vertically integrated biosimilars platform with more than 20 programs and access to over $300 million in biologic loss‑of‑exclusivity opportunities over the next decade.

Robust Q1 2026 Financial Performance

Preliminary first‑quarter numbers showed solid momentum, with total net revenue rising 4% year over year to $723 million. Adjusted EBITDA jumped 19% to $202 million and adjusted EPS climbed 29% to $0.27, while Affordable Medicines grew 2% to $423 million and Specialty revenue surged 23% to $133 million.

Margin Expansion and Operating Leverage

Profitability continued to improve, led by Affordable Medicines, where segment gross margin reached 47.3%, up 320 basis points from a year earlier. Management reported around 500 basis points of adjusted gross margin expansion overall and lifted its 2026 full‑year gross margin target to roughly 45%, about 200 basis points higher than 2025.

Pipeline and Launch Cadence

The company laid out an ambitious launch schedule, projecting multiple biosimilar introductions each year and six commercial biosimilars on the market by 2027. Key assets include Avastin and denosumab, with lanreotide expected to win approval in the third quarter and Xolair targeted for clearance by year‑end, plus six or more additional approvals by 2030.

Manufacturing Capacity and Scalability

Kashiv adds four research and manufacturing sites, roughly 600 employees and more than $900 million of historical investment, which Amneal plans to leverage for scale. Drug substance capacity is projected to rise from 26,000 liters in 2026 to 75,000 liters by 2028, supported by about $30 million to $50 million in annual capital spending over the next two to three years.

Financial Synergies and Long-Term Growth Targets

Management is targeting cumulative financial synergies of $400 million to $500 million over time from the combined platform. By 2030, the company expects revenue to increase by about $1.2 billion, or roughly 40% over 2026, and EPS to be about $0.70 higher, a gain of around 70%, with biosimilars contributing $1.0 billion to $1.3 billion in sales.

Improving Leverage Despite Deal Funding

Amneal highlighted steady balance sheet progress, with net leverage improving to 3.5 times adjusted EBITDA as of March 2026 from 3.9 times a year earlier. After funding the Kashiv deal, leverage is expected to tick up to about 3.7 times by the end of 2026, but management outlined a path to bring that below three times by 2028.

Specialty Launch Momentum

Specialty products continued to gain traction, supporting the company’s shift toward higher‑margin, branded therapies. CREXONT generated $21 million in first‑quarter revenue, backed by favorable Phase IV data, while newly launched Brekiya grew rapidly, posting $4.6 million versus $1.6 million in the prior quarter.

Near-Term Leverage Increase and Transaction Costs

Executives cautioned that the acquisition’s funding mix, which includes cash and some incremental debt, will temporarily push leverage higher around 3.7 times in 2026. They also flagged near‑term transaction and integration costs that will weigh on cash flows before deleveraging resumes in 2027 and accelerates thereafter.

Upfront Dilution and Contingent Consideration

The Kashiv deal includes an equity component of roughly $29 million in Amneal shares, translating to about 8% dilution for existing holders. Additional contingent milestone payments of up to $350 million and potential royalties will introduce future variability in cash needs and earnings, depending on development and commercial success.

2027 Guidance and Near-Term Growth Pace

For 2027, management outlined adjusted EBITDA guidance of $820 million, implying only about 9% growth versus the midpoint of 2026 expectations. Leaders described this as a period of modest near‑term dilution as the Kashiv integration progresses, with greater accretion anticipated from 2028 onward as biosimilar launches ramp.

Q1 / Full-Year Gross Margin Normalization Risk

While first‑quarter gross margins were particularly strong, with some commentary pointing to an implied run rate near 48%, the company does not expect that level to persist. Instead, management reaffirmed a more conservative full‑year 2026 margin outlook of roughly 45%, signaling normalization from the Q1 spike as mix and timing effects balance out.

Operational and Execution Complexity

Management acknowledged that integrating end‑to‑end biologics research and manufacturing brings significant execution risk, given long timelines and strict regulatory hurdles. Each biosimilar program is estimated to require $50 million to $75 million in investment and five to seven years of development, underscoring the capital‑intensive nature of the strategy.

AvKARE Revenue Mix Shift

At AvKARE, first‑quarter revenue declined by $6 million, or 4% year over year, as Amneal deliberately scaled back low‑margin distribution activity. However, the shift toward higher‑margin government channels lifted AvKARE’s gross margin by roughly 690 basis points, improving profitability even as top‑line growth slowed.

Guidance and Long-Term Outlook

Amneal raised its stand‑alone 2026 forecast after the strong first quarter, targeting company‑wide gross margins around 45% versus 42.9% in 2025 and aiming for mid‑ to high‑40s over time. Looking ahead to 2030, leadership is guiding to total revenue between $4.3 billion and $4.5 billion and substantial EPS growth, with biosimilars expected to emerge as a billion‑dollar‑plus revenue pillar.

Amneal’s earnings call painted the picture of a company in transition, leveraging a healthier balance sheet and expanding margins to fund a sizable bet on biosimilars. While investors will need to navigate near‑term leverage, dilution and execution risks, the management team emphasized the potential for Kashiv to reshape Amneal’s growth profile and deliver stronger earnings power over the coming decade.